OTC : BPTH
$0.0 (10.71%)
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Vikram Paul Grover |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BPTH |
| CUSIP | 09057N409 |
| CIK | 0001133818 |
| Web | https://www.biopathholdings.com |
| Phone | 832 742 1357 |
| Currency | USD |
| Employees | 1 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.06 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.07 |
| Quick Ratio | 0.07 |
| Cash Ratio | 0.00 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -0.03 |
| Price / Cash Flow | -1.13 |
| Price / Book | -0.04 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.1 |
| Trailing P/E Ratio | -0.05 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$8.67M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 76.46% |
| Return on Assets | -899.85% |
Financials Score
| AltmanZ Score | -304.49 |
| Piotroski Score | 1.00 |
| Working Capital | -8.47M |
| Total Assets | 677K |
| Ebit | -5.75M |
| Market Cap | 373.69K |
| Total Liabilities | 9.16M |
About Bio-Path Holdings, Inc. (OTC:BPTH) Stock
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is ... in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Frequently Asked Questions
What is the current Bio-Path Holdings, Inc. (BPTH) stock price?
Bio-Path Holdings, Inc.(OTC:BPTH) stock price is $0.03875 in the last trading session. During the trading session, BPTH stock reached the peak price of $0.17 while $0.01 was the lowest point it dropped to. The percentage change in BPTH stock occurred in the recent session was 10.71% while the dollar amount for the price change in BPTH stock was $0.0.
BPTH's industry and sector of operation?
The OTC listed BPTH is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of BPTH?
Ana Tari Ashizawa
| Senior Vice President of Research, Development & Clinical Design
Douglas Morris
| Co-Founder, Director of Investor Relations & Secretary
Anthony Price
| Senior Vice President of Finance, Accounting & Administration
Michael Hickey
| Member of Scientific Advisory Board & VP of Clinical Operations
Vikram Paul Grover
| President, Chief Executive Officer, Chief Financial Officer & Director
How many employees does BPTH have?
Number of BPTH employees currently stands at 1. BPTH operates from 4710 Bellaire Boulevard, Bellaire, TX 77401, US.
Link for BPTH official website?
Official Website of BPTH is: https://www.biopathholdings.com
How do I contact BPTH?
BPTH could be contacted at phone #832 742 1357 and can also be accessed through its website. BPTH operates from 4710 Bellaire Boulevard, Bellaire, TX 77401, US.
How many shares of BPTH are traded daily?
The average number of BPTH shares traded daily for last 3 months was 32.68K.
What is the market cap of BPTH currently?
The market value of BPTH currently stands at $362.01K with its latest stock price at $0.03875